Synopsis
Synopsis
0
CEP/COS
0
VMF
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Finished Drug Prices
NA
1. 2-(4-chlorobenzoylamino)-3-(2(1h)-quinolinon-4-yl)propionic Acid
2. Opc 12759
3. Opc-12759
4. Rebamipide, (+)-isomer
5. Rebamipide, (-)-isomer
1. 90098-04-7
2. Proamipide
3. Mucosta
4. 111911-87-6
5. Opc-12759
6. Rebamipide Hydrate
7. Pramipide
8. Rebator
9. 2-(4-chlorobenzoylamino)-3-(1,2-dihydro-2-oxo-4-quinolyl)propionic Acid
10. 139344-42-6
11. 2-[(4-chlorobenzoyl)amino]-3-(2-oxo-1h-quinolin-4-yl)propanoic Acid
12. Nsc-758955
13. 2-(4-chlorobenzamido)-3-(2-oxo-1,2-dihydroquinolin-4-yl)propanoic Acid
14. Lr583v32zr
15. Mfcd00866895
16. Ncgc00095161-01
17. 2-(4-chlorobenzamido)-3-[2(1h)-quinolinon-4-yl]propionic Acid
18. Dsstox_cid_25937
19. Dsstox_rid_81235
20. Dsstox_gsid_45937
21. Rebamipidum
22. Rebamipide [inn:jan]
23. 2-[(4-chlorobenzoyl)amino]-3-(2-hydroxyquinolin-4-yl)propanoic Acid
24. Rebamipidum [inn-latin]
25. 2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1h-quinolin-4-yl)propanoic Acid
26. Opc 12759
27. Cas-90098-04-7
28. Ccris 3585
29. Sr-05000001520
30. Unii-lr583v32zr
31. N-[(4-chlorophenyl)carbonyl]-3-(2-oxo-1,2-dihydroquinolin-4-yl)alanine
32. Dispersered72
33. 2-[(4-chlorophenyl)carbonylamino]-3-(2-oxidanylidene-1h-quinolin-4-yl)propanoic Acid
34. Rebamipide-[d4]
35. Mucosta (tn)
36. Rebamipide [mi]
37. Rebamipide [inn]
38. Rebamipide [jan]
39. Spectrum2_000039
40. Spectrum3_001959
41. Rebamipide (jp17/inn)
42. (+-)-2-(4-chlorobenzoylamino)-3-(2(1h)-quinolinon-4-yl)propionic Acid
43. (+-)-1,2-dihydro-alpha-((4-chlorobenzoyl)amino)-2-oxo-4-quinolinepropanoic Acid
44. Rebamipide [who-dd]
45. Bspbio_003559
46. Gtpl871
47. Mls006011883
48. Schembl221527
49. Spectrum1505310
50. Spbio_000137
51. Rebamipide 111911-87-6
52. Chembl1697771
53. Dtxsid8045937
54. Chebi:93814
55. Kbio3_002880
56. Opc-759
57. Hms1922b20
58. Hms2090l13
59. Hms3655l11
60. Hms3714a15
61. Pharmakon1600-01505310
62. Bcp07230
63. Hy-b0360
64. Opc12759
65. Tox21_111460
66. Bbl011328
67. Ccg-39619
68. Nsc758955
69. S2032
70. Stk577121
71. Stl146407
72. 2-(4-chlorobenzamido)-3-(2-oxo-1,2-dihydro-4-quinolyl)propanoic Acid
73. Akos005501649
74. Akos005721106
75. Tox21_111460_1
76. Ac-6841
77. Ac-7588
78. Db11656
79. Nsc 758955
80. 2-(4-chloro-benzoylamino)-3-(2-oxo-1,2-dihydro-quinolin-4-yl)-propionic Acid
81. 4-quinolinepropanoic Acid, 1,2-dihydro-alpha-((4-chlorobenzoyl)amino)-2-oxo-, (+-)-
82. Ncgc00095161-02
83. Ncgc00095161-03
84. Ncgc00095161-04
85. Ncgc00095161-05
86. Bc164330
87. Smr003309276
88. Sy057250
89. Vs-02924
90. Sbi-0207054.p001
91. Ft-0630971
92. Ft-0655225
93. R0085
94. Sw199113-2
95. D01121
96. Ab01275518-01
97. Ab01275518_02
98. Ab01275518_03
99. 911r876
100. A802443
101. A843443
102. A900081
103. Q-201660
104. Q7301602
105. Sr-05000001520-1
106. Sr-05000001520-2
107. Sr-05000001520-3
108. Brd-a15909516-001-02-5
109. Brd-a15909516-001-03-3
110. 2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl)propionic Acid
111. 2-(4-chlorobenzoylamino)-3-[2(1h)-quinolinon-4-yl] Propionic Acid
112. 2-(4-chlorobenzoylamino)-3-[2(1h)-quinolinon-4-yl]propionic Acid
113. N-[(4-chlorophenyl)carbonyl]-3-(2-hydroxyquinolin-4-yl)alanine
114. 2-(4-chlorobenzamido)-3-(2-oxo-1,2-dihydroquinolin-4-yl)propanoicacid
115. 2-(4-chlorobenzoylamino)-3-(2-oxo-1,2-dihydroquinolin-4-yl)propionic Acid
116. 4-quinolinepropanoicacid,a-[(4-chlorobenzoyl)amino]-1,2-dihydro-2-oxo-
117. (+/-)-.alpha.-(p-chlorobenzamido)-1,2-dihydro-2-oxo-4-quinolinepropionic Acid
118. (+/-)-2-(4-chlorobenzoylamino)-3-(2(1h)-quinolinon-4-yl)-propionic Acid
119. 2-[(4-chlorophenyl)formamido]-3-(2-oxo-1,2-dihydroquinolin-4-yl)propanoic Acid
120. 4-quinolinepropanoic Acid, .alpha.-((4-chlorobenzoyl)amino)-1,2-dihydro-2-oxo-
Molecular Weight | 370.8 g/mol |
---|---|
Molecular Formula | C19H15ClN2O4 |
XLogP3 | 2.4 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 5 |
Exact Mass | 370.0720347 g/mol |
Monoisotopic Mass | 370.0720347 g/mol |
Topological Polar Surface Area | 95.5 Ų |
Heavy Atom Count | 26 |
Formal Charge | 0 |
Complexity | 598 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
Antioxidants
Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)
Anti-Ulcer Agents
Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)
A - Alimentary tract and metabolism
A02 - Drugs for acid related disorders
A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)
A02BX - Other drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)
A02BX14 - Rebamipide
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15001
Submission : 2000-08-10
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21700
Submission : 2008-06-09
Status : Inactive
Type : II
Registration Number : 228MF10089
Registrant's Address : Jiangxi Fengxin Industrial Park, Fengxin, 330700, Jiangxi Province, P. R. China
Initial Date of Registration : 2016-04-15
Latest Date of Registration :
NDC Package Code : 52048-1982
Start Marketing Date : 2009-07-17
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Hansol Pharma Co., Ltd.
Registration Date : 2024-02-22
Registration Number : 20070504-4-B-240-14(45)
Manufacturer Name : Jiangxi Synergy Pharmaceutical Co.,Ltd
Manufacturer Address : Jiangxi Fengxin Industrial Park, Fengxin 330700 Jiangxi Province, China
Registration Number : 230MF10081
Registrant's Address : Zhejiang Provincial Chemical and Medical Raw Material Base Linhai Zone Duqiao town, Linhai City, Zhejiang Province, China
Initial Date of Registration : 2018-07-09
Latest Date of Registration :
Registrant Name : Masung LS Co., Ltd.
Registration Date : 2021-01-07
Registration Number : 20210107-4-B-439-22
Manufacturer Name : Zhejiang Liaoyuan Pharmaceutical Co., Ltd.
Manufacturer Address : Zhejiang Provincial Chemical and Medical Raw Material Base Linhai Zone, Duqiao Town, Linhai City, Zhejiang Province, 317016, China
Registration Number : 218MF10919
Registrant's Address : 5, Soonwha-dong, Joong-Ku, Seoul. Korea
Initial Date of Registration : 2006-11-21
Latest Date of Registration :
Registrant Name : Dongwha Pharmaceutical Co., Ltd.
Registration Date : 2005-08-31
Registration Number : 20050831-4-B-21-09
Manufacturer Name : Dongwha Pharmaceutical Co., Ltd.
Manufacturer Address : 167, Chungju Industrial Complex 1-ro, Chungchu-si, Chungcheongbuk-do
Registration Number : 229MF10220
Registrant's Address : Plot No. 370, Industrial Area, Phase-II, Panchkula, Haryana State, India
Initial Date of Registration : 2017-12-18
Latest Date of Registration :
Date of Issue : 2019-08-13
Valid Till : 2022-08-12
Written Confirmation Number : WC-0171
Address of the Firm :
Registration Number : 222MF10259
Registrant's Address : 25, Barangongdan-ro, Hyangnam-eup, Hwaseong-si, Gyeonggi-do Korea
Initial Date of Registration : 2010-11-18
Latest Date of Registration :
Registrant Name : Polaris AI Pharma Co., Ltd.
Registration Date : 2012-09-27
Registration Number : 20120927-4-B-353-19
Manufacturer Name : Polaris AI Pharma Co., Ltd.
Manufacturer Address : 25 Balan Industrial Complex-ro, Hyangnam-eup, Hwaseong-si, Gyeonggi-do, 34 Block 10-11, Balan Industrial Complex
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Market Place
ABOUT THIS PAGE
80
PharmaCompass offers a list of Rebamipide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Rebamipide manufacturer or Rebamipide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Rebamipide manufacturer or Rebamipide supplier.
PharmaCompass also assists you with knowing the Rebamipide API Price utilized in the formulation of products. Rebamipide API Price is not always fixed or binding as the Rebamipide Price is obtained through a variety of data sources. The Rebamipide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Rebamipide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Rebamipide, including repackagers and relabelers. The FDA regulates Rebamipide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Rebamipide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Rebamipide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Rebamipide supplier is an individual or a company that provides Rebamipide active pharmaceutical ingredient (API) or Rebamipide finished formulations upon request. The Rebamipide suppliers may include Rebamipide API manufacturers, exporters, distributors and traders.
click here to find a list of Rebamipide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Rebamipide DMF (Drug Master File) is a document detailing the whole manufacturing process of Rebamipide active pharmaceutical ingredient (API) in detail. Different forms of Rebamipide DMFs exist exist since differing nations have different regulations, such as Rebamipide USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Rebamipide DMF submitted to regulatory agencies in the US is known as a USDMF. Rebamipide USDMF includes data on Rebamipide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Rebamipide USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Rebamipide suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Rebamipide Drug Master File in Japan (Rebamipide JDMF) empowers Rebamipide API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Rebamipide JDMF during the approval evaluation for pharmaceutical products. At the time of Rebamipide JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Rebamipide suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Rebamipide Drug Master File in Korea (Rebamipide KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Rebamipide. The MFDS reviews the Rebamipide KDMF as part of the drug registration process and uses the information provided in the Rebamipide KDMF to evaluate the safety and efficacy of the drug.
After submitting a Rebamipide KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Rebamipide API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Rebamipide suppliers with KDMF on PharmaCompass.
A Rebamipide written confirmation (Rebamipide WC) is an official document issued by a regulatory agency to a Rebamipide manufacturer, verifying that the manufacturing facility of a Rebamipide active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Rebamipide APIs or Rebamipide finished pharmaceutical products to another nation, regulatory agencies frequently require a Rebamipide WC (written confirmation) as part of the regulatory process.
click here to find a list of Rebamipide suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Rebamipide as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Rebamipide API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Rebamipide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Rebamipide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Rebamipide NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Rebamipide suppliers with NDC on PharmaCompass.
Rebamipide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Rebamipide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Rebamipide GMP manufacturer or Rebamipide GMP API supplier for your needs.
A Rebamipide CoA (Certificate of Analysis) is a formal document that attests to Rebamipide's compliance with Rebamipide specifications and serves as a tool for batch-level quality control.
Rebamipide CoA mostly includes findings from lab analyses of a specific batch. For each Rebamipide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Rebamipide may be tested according to a variety of international standards, such as European Pharmacopoeia (Rebamipide EP), Rebamipide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Rebamipide USP).